A phase ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia

Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller, Prapti A. Patel, Alexander I. Spira, Michaela L. Tsai, Errin Samuelsz, Sandra L. Silberman, Mark Erlander, Eunice S. Wang